| Founded | 2017 |
|---|---|
| Closed | 2022 |
| Country | USA |
| Sector | Biotech |
| Collapse type | Fire Sale |
| Founder | Ian Henig |
Vincera Pharma
"Immune toxicity in one-third of patients ended this blood cancer drug's career fast."
Distressed acquisition below last-round valuation
Key Events Timeline
Vincera Pharma, a Philadelphia-based oncology biotech developing PI3K delta inhibitor VIP152 for hematologic cancers, merged with Equillium in late 2022 in a distressed deal after Phase 1/2 data showed severe immune toxicity including pneumonitis and colitis in 35% of patients.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →Vincera Pharma followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →